← Back to Search

Omega-3 Fatty Acid

Fish Oil + Salsalate for Diabetic Neuropathy

Phase 1 & 2
Recruiting
Led By Rodica Pop-Busui, MD
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
T2D according to American Diabetes Association (ADA) criteria
Age ≥ 18 yr
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, 16 weeks and 24 weeks.
Awards & highlights

Study Summary

This trial is studying the combination of fish oil and salsalate to see if it is an effective treatment for diabetic peripheral neuropathy (DPN). DPN is a common complication of diabetes that can lead to severe pain, sensory deficits, foot ulcers, and amputations. There is no currently no effective treatment for DPN.

Who is the study for?
Adults over 18 with type 2 diabetes and diabetic peripheral neuropathy can join this trial. They should have an HbA1c level below 9.5% and be willing to use contraception if necessary. People with other types of neuropathy, severe kidney issues, recent transplants, or certain medical conditions that could interfere with the study cannot participate.Check my eligibility
What is being tested?
The trial is testing whether taking fish oil capsules (rich in omega-3 fatty acids) alone or combined with salsalate tablets can help people with diabetic nerve pain by changing their blood lipid profile and increasing anti-inflammatory metabolites.See study design
What are the potential side effects?
Possible side effects include minor risks associated with fish oil such as a fishy aftertaste, nausea, and loose stools. Salsalate may cause stomach upset, ringing in the ears, or allergic reactions for those sensitive to it.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Type 2 Diabetes.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, 16 weeks and 24 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 16 weeks and 24 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline of omega-3 index at 16 and 24 weeks
Secondary outcome measures
Change from baseline in diabetic peripheral neuropathy symptoms score after 24 weeks using the Michigan Neuropathy Screening Instrument.
Change from baseline in fasting blood glucose after 16 and 24 weeks.
Change from baseline in fasting blood lipids (triglycerides and low- and high-density cholesterol) after 16 and 24 weeks.
+12 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Fish oil capsulesExperimental Treatment1 Intervention
Subjects will be randomized for the treatment of fish oil capsules. Subjects will take daily supplements of two or four fish oil capsules per day, 2 and 4 g respectively. Treatment will continue for 16 weeks. Fish oil capsules are enriched in omega-3 polyunsaturated fatty acids.
Group II: Fish oil and SalsalateExperimental Treatment2 Interventions
Salsalate is a non-steroid anti-inflammatory drug. Subjects taking 2 or 4g of fish oil capsules will be randomized to take in addition 1.5 or 3.0 g of salsalate per day. The combined treatment of fish oil and salsalate will continue for 8 weeks.

Find a Location

Who is running the clinical trial?

University of IowaLead Sponsor
447 Previous Clinical Trials
879,622 Total Patients Enrolled
University of MichiganOTHER
1,797 Previous Clinical Trials
6,377,958 Total Patients Enrolled
Rodica Pop-Busui, MDPrincipal InvestigatorProfessor of Medicine

Media Library

Fish Oil Concentrate (Omega-3 Fatty Acid) Clinical Trial Eligibility Overview. Trial Name: NCT05169060 — Phase 1 & 2
Diabetic Neuropathy Research Study Groups: Fish oil capsules, Fish oil and Salsalate
Diabetic Neuropathy Clinical Trial 2023: Fish Oil Concentrate Highlights & Side Effects. Trial Name: NCT05169060 — Phase 1 & 2
Fish Oil Concentrate (Omega-3 Fatty Acid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05169060 — Phase 1 & 2
Diabetic Neuropathy Patient Testimony for trial: Trial Name: NCT05169060 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many study participants are enrolled in this clinical research endeavor?

"This trial has closed and is no longer accepting patients. The initial posting was on November 1st 2022, and the last update occured on the same day. However, if you're searching for other trials there are presently 175 studies enrolling those suffering from diabetic neuralgia and 14 more looking at Fish Oil Concentrate 1000 Mg Oral Capsule as a potential treatment option."

Answered by AI

In what conditions is Fish Oil Concentrate, 1000 Mg Oral Capsule commonly employed?

"Dietary and nutritional therapies commonly call for Fish Oil Concentrate, 1000 Mg Oral Capsule as a form of supplement. It has also been known to be effective at treating conditions related to pregnancy or postnatal care, as well as boosting breast milk production."

Answered by AI

Could you elucidate any other research projects involving Fish Oil Concentrate, 1000 Mg Oral Capsule?

"As of now, 14 research studies are taking place for Fish Oil Concentrate, 1000 Mg Oral Capsule with 3 in their third phase. The majority of the trials take place within Mexico City but 22 different locations host these investigations."

Answered by AI

Are there still openings for prospective participants in this research experiment?

"This research is no longer recruiting participants. The initial post was published on November 1st 2022 and the last update occurred at the same time. If you are seeking further medical trials, there are 175 studies currently looking for people with diabetic neuralgia and 14 investigations involving Fish Oil Concentrate, 1000 Mg Oral Capsule that need volunteers."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Michigan
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+
0
What site did they apply to?
University of Michigan

Why did patients apply to this trial?

Trying to help find a solution to help and cure diabetes.
PatientReceived 1 prior treatment
~58 spots leftby Jul 2025